Exhibit 99.1

STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

 

 

“During the second quarter of 2024, we continued to make financial and strategic progress.  Revenue grew 2% year-over-year to $8.4M, gross margins improved from 52.3% a year ago to 58.5%, and our cost control measures helped reduce total operating expenses by 14% year-over-year, or approximately $900,000.  These factors helped reduce our operating loss from $2.0M in the second quarter of 2023 to a loss of $0.5 million in the recently completed quarter,” commented STRATA’s President and CEO Dr. Dolev Rafaeli.  “Furthermore, our total cash increased sequentially from $6.6 million to $6.8 million in the second quarter of 2024, largely due to receipt of $864,000 in the second quarter of 2024 from the Employee Retention Credit under the CARES Act.

“We continue to ramp our DTC marketing spend and expect this trend to continue across the remainder of 2024.  Renewed focus on a DTC campaign is a key strategy for STRATA, and we are seeing early positive signs that suggest an emphasis on DTC is paying off.  The number of XTRAC^® patient appointments that were sourced via DTC in the second quarter grew sequentially, while cost-per-lead and cost-per-appointment were lower than those in 2021, the last time the company was using DTC at a comparable scale. These favorable metrics have enabled an expansion of our marketing efforts to 28 active designated marketing areas, or DMAs, and leads are now generally driven nationwide with further focus on areas where growth is needed strategically.

“Our strategic efforts to optimize our installed base of devices also continues, with the ultimate goal of increasing the utilization of our devices.  Quite simply, if a dermatology practice has one of our devices installed but is not using it, then we prefer to remove that device and find a practice that will be more active in performing multiple daily procedures with it.  To this end, our domestic base of installed XTRAC^® devices were down from 907 units at the end of March 2024 to 882 units at the end of June, consistent with our plan to shrink our installed base of devices in 2024.

“With TheraClear^®X, our installed base of devices with dermatology practices continues to increase, with that base growing from 104 devices at the end of March 2024 to 117 devices at the end of June. Moreover, the number of patients pre-approved by individual payers grew sequentially, with the northeast region leading that expansion. Two studies were recently published in respected journals that highlight the effectiveness and safety with our TheraClear^®X photopneumatic devices for mild-to-moderate acne, and we will continue to educate physicians and patients alike about this relatively new treatment offering that can be quite effective both as monotherapy and as an adjuvant.

“Lastly, in July, we completed a financing that increased our cash balance by $2.1 million in gross proceeds.  This offering had participation from insiders and some current institutional shareholders that accounted for roughly half of the amount raised, which shows conviction in the leadership and corporate strategy.  We look forward to continued progress with our turnaround with an eye towards profitability and positive cash flow and will share additional corporate developments as warranted,” concluded Dr. Rafaeli.

Revenue for the second quarter of 2024 was $8.4 million, as compared to revenue of $8.3 million for the second quarter of 2023.  Global recurring revenue for the second quarter of 2024 was $5.3 million, as compared to global recurring revenue of $5.5 million for the second quarter of 2023.  Equipment revenue was $3.1 million for the second quarter of 2024, as compared to $2.8 million for the second quarter of 2023.

Gross profit for the second quarter of 2024 was $4.9 million, or 58.5% of revenue, as compared to $4.3 million, or 52.3% of revenue, for the second quarter of 2023.

Selling and marketing costs for the second quarter of 2024 were $3.0 million, as compared to $3.4 million for the second quarter of 2023.  General and administrative costs for the second quarter of 2024 were $2.2 million, as compared to $2.5 million for the second quarter of 2023.

Net loss for the second quarter of 2024 was $0.1 million, or a net loss of $0.03 per basic and diluted common share, as compared to a net loss of $3.1 million, or a net loss of $0.90 per basic and diluted common share, in the second quarter of 2023.

Cash, cash equivalents, and restricted cash at June 30, 2024 were $6.8 million.

STRATA management will host a conference call today at 4:30 p.m. ET to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

To listen to the conference call, interested parties within the U.S. should dial 1-877-270-2148 (domestic) or 1-412-902-6510 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 2Q24 Earnings Webcast.

A telephonic replay of the call will be available until August 21, 2024 by dialing 1-877-344-7529 (or 1-412-317-0088 for international callers) and using replay access code 7605445.  To access the replay using an international dial-in number, please see here.

A webcast earnings call replay will be available approximately one hour after the live call until February 14, 2025.

Non-GAAP Financial Measures

STRATA has determined to supplement its consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, “Earnings Before Interest, Taxes, Depreciation, and Amortization.”

These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. STRATA considers these non-GAAP measures in addition to its results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers’ overall understanding of STRATA’s current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, STRATA believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, STRATA believes non-GAAP measures enhance the comparability of results against prior periods.

XTRAC Gross Domestic Recurring Billings

XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.

The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the second quarter and first six months of 2024 and 2023 (in thousands), respectively:

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:

CORE IR

516-222-2560

IR@strataskin.com

STRATA Skin Sciences, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

STRATA Skin Sciences, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

STRATA Skin Sciences, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)